longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Argenx

ARGX

995.7701.13% ( +11.080 )
Closed: Sep 17, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 36.31, within the reasonable range, cheaper than 36.4% of the time in the past 1 years, and the industry ranks 48/601, the industry Median -2.36.

36.31xP/E
$995.77Stock price
$27.42Earnings per share
36.31xP/E
Stock price$995.77Earnings per share$27.42

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
35.22x
Typical range
33.18x–37.67x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
ARGXUSArgenx
36.31x37.17%$62.27B
ALNYUSAlnylam Pharma
42.40x183.00%$32.85B
BIIBUSBiogen
38.78x30.25%$32.37B
HALOUSHalozyme Therap
30.10x181.51%$12.45B
KRYSUSKrystal Biotech
41.52x10.83%$10.03B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.